TY - JOUR
T1 - Three Prospective Case Studies Examining Mifepristone's Efficacy in Patients with Treatment-Resistant PTSD
AU - Van Minnen, Agnes
AU - Vos, Lizelotte
AU - Bet, Pierre M.
AU - De Jongh, Ad
AU - Linsen, Felix
AU - Van Marle, Hein J.F.
AU - Meijer, Onno C.
AU - Otte, Willem M.
AU - Russcher, Marije
AU - Vinkers, Christiaan H.
N1 - Publisher Copyright:
© 2024 Agnes van Minnen et al.
PY - 2024
Y1 - 2024
N2 - Despite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in treatment-resistant PTSD patients. Three patients with PTSD who were resistant to standard psychological and pharmacological treatments were prescribed mifepristone (600-1,200 mg/day) for 1 week. A baseline-controlled single-case design was used, involving a 2-week baseline phase (no intervention), a 1-week intervention phase (mifepristone), and a 2-week postintervention phase. The primary outcome measure, self-reported PTSD symptom severity (PCL-5), was assessed daily, with participants providing their own control condition. Two of the three patients experienced a significant reduction in PTSD symptom severity after the intervention phase and no longer met the diagnostic criteria for PTSD. These positive results were maintained during long-term follow-up. These findings support the potential effectiveness of mifepristone in the treatment of patients with treatment-resistant PTSD. However, our findings must be interpreted with caution, and further studies with larger sample sizes and more rigorous designs are necessary to confirm the promising results.
AB - Despite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in treatment-resistant PTSD patients. Three patients with PTSD who were resistant to standard psychological and pharmacological treatments were prescribed mifepristone (600-1,200 mg/day) for 1 week. A baseline-controlled single-case design was used, involving a 2-week baseline phase (no intervention), a 1-week intervention phase (mifepristone), and a 2-week postintervention phase. The primary outcome measure, self-reported PTSD symptom severity (PCL-5), was assessed daily, with participants providing their own control condition. Two of the three patients experienced a significant reduction in PTSD symptom severity after the intervention phase and no longer met the diagnostic criteria for PTSD. These positive results were maintained during long-term follow-up. These findings support the potential effectiveness of mifepristone in the treatment of patients with treatment-resistant PTSD. However, our findings must be interpreted with caution, and further studies with larger sample sizes and more rigorous designs are necessary to confirm the promising results.
UR - http://www.scopus.com/inward/record.url?scp=85192780554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85192780554&partnerID=8YFLogxK
U2 - 10.1155/2024/4768647
DO - 10.1155/2024/4768647
M3 - Article
AN - SCOPUS:85192780554
SN - 2090-682X
VL - 2024
SP - 1
EP - 6
JO - Case Reports in Psychiatry
JF - Case Reports in Psychiatry
M1 - 4768647
ER -